Walking is a vital component of physical activity in patients with chronic obstructive pulmonary disease (COPD). Exertional multidimensional breathlessness in daily life can reduce walking speed and time in patients with established COPD [1]. Improvement in breathlessness beyond a minimal clinically significant difference brought about by pulmonary rehabilitation, pharmaceutical bronchodilators and opioids has been reported [2–4]. However, despite guideline-directed disease-specific therapy, some patients with COPD experience residual breathlessness. Therefore, the application of a novel symptom-based treatment that is widely available will benefit patients with long-term breathlessness.